000			nab a22 7a 4500
999			_c17223 _d17223
003			PC17223
005			20230213125457.0
008			230213b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9389 _aMartínez López, Joaquín _eHematología y Hemoterapia
245	0	0	_aPatterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. _h[artículo]
260			_bLeukemia research reports, _c2015
300			_a4(2):64-9.
500			_aFormato Vancouver: López A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI et al. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leuk Res Rep. 2015 Sep 24;4(2):64-9.
501			_aPMID: 26500850 PMC4588395
504			_aContiene 23 referencias
520			_aWe report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).
710			_9297 _aServicio de Hematología y Hemoterapia
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588395/ _yAcceso libre
942			_2ddc _cART _n0